source
- FDA approves Regeneron's Livsayis, first RNAi therapy for generalized myasthenia gravisThe Food and Drug Administration approved Regeneron's Livsayis, an RNA interference drug for generalized myasthenia gravis, marking the company's first marketed RNAi therapy. The drug, originally…
- Congressional biotech panel cautions on rising China licensing dealsA bipartisan congressional commission that advises on U.S. biotech competitiveness is concluding its work with a focus on partnerships with Chinese firms. The panel highlighted the growing number…